Sengottuvelu Gunasekaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sengottuvelu Gunasekaran has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
Ravindran Rajendran
Apollo Hospitals, Chennai 06, India
8 shared publications- Ashok Seth
Fortis Escorts Heart Institute New Delhi India
5 shared publications - Osama I. I. Soliman
Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland
5 shared publications - Ahmed Elkoumy
Department of Cardiology, Saolta Group, Galway University Hospital, Galway, Ireland
4 shared publications - Andreas Baumbach
Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
4 shared publications John Jose
Christian Medical College and Hospital, Vellore, Tamil Nadu, India
4 shared publications
Latest Publications
- 23 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 2005-2017
Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up
Background: Recently, Acurate neo2 (ACN2; Boston Scientific, US) and Sapien‐3 series (Edwards Lifesciences, US) were compared in the IDE trial failing to demonstrate non‐inferiority of ACN2. The Myval series (MyV), an alternative balloon‐expandable device, demonstrated non‐inferiority compared to Sapien‐3 and Evolut (Medtronic, US) in the LANDMARK trial. However, no direct comparison exists between ACN2 and MyV. Aims: We aimed to compare mid‐term clinical and hemodynamic outcomes of the ACN2 and MyV transcatheter heart valves. Methods: This multicenter retrospective analysis included patients implanted with ACN2 and MyV series devices. The primary objective was to assess 1‐year mortality and stroke rates. Secondary outcomes included technical success, mortality, stroke, residual aortic regurgitation (AR), mean aortic gradients, and new permanent pacemaker implantation (PPI) rates up to 4 years. A matched comparison adjusting for clinical and anatomical characteristics was performed and echocardiograms were centrally analyzed. Results: A total of 545 patients (ACN2: 144; MyV: 401) from nine institutions were included. Matched technical success rates were 87.6% and 94.4%, p = 0.180 (90.3% for ACN2 and 97% for MyV; p < 0.001 in unmatched). In‐hospital matched PPI rates were 10.1% for ACN2 and 9% for MyV. At 4 years, matched residual ≥ moderate AR rates were similar (ACN2: 15.8% vs. MyV: 21.1%, p = 0.706), though ACN2 showed better mean aortic gradients (9.2 ± 4.2 vs. 13.1 ± 5.4, p = 0.001) and effective orifice area. Unmatched mortality + stroke rates were comparable but lower for ACN2 after matching (3.4% vs. 15.7%, p = 0.005). Importantly, cardiovascular mortality (3.4% for ACN2 and 5.6% for MyV, p = 0.720) and valve‐related deaths were comparable. Conclusion: ACN2 showed superior long‐term hemodynamics and lower matched 4‐year mortality and stroke rates, though cardiovascular mortality and valve‐related deaths were comparable.
- 23 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 2005-2017
Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up
Background: Recently, Acurate neo2 (ACN2; Boston Scientific, US) and Sapien‐3 series (Edwards Lifesciences, US) were compared in the IDE trial failing to demonstrate non‐inferiority of ACN2. The Myval series (MyV), an alternative balloon‐expandable device, demonstrated non‐inferiority compared to Sapien‐3 and Evolut (Medtronic, US) in the LANDMARK trial. However, no direct comparison exists between ACN2 and MyV. Aims: We aimed to compare mid‐term clinical and hemodynamic outcomes of the ACN2 and MyV transcatheter heart valves. Methods: This multicenter retrospective analysis included patients implanted with ACN2 and MyV series devices. The primary objective was to assess 1‐year mortality and stroke rates. Secondary outcomes included technical success, mortality, stroke, residual aortic regurgitation (AR), mean aortic gradients, and new permanent pacemaker implantation (PPI) rates up to 4 years. A matched comparison adjusting for clinical and anatomical characteristics was performed and echocardiograms were centrally analyzed. Results: A total of 545 patients (ACN2: 144; MyV: 401) from nine institutions were included. Matched technical success rates were 87.6% and 94.4%, p = 0.180 (90.3% for ACN2 and 97% for MyV; p < 0.001 in unmatched). In‐hospital matched PPI rates were 10.1% for ACN2 and 9% for MyV. At 4 years, matched residual ≥ moderate AR rates were similar (ACN2: 15.8% vs. MyV: 21.1%, p = 0.706), though ACN2 showed better mean aortic gradients (9.2 ± 4.2 vs. 13.1 ± 5.4, p = 0.001) and effective orifice area. Unmatched mortality + stroke rates were comparable but lower for ACN2 after matching (3.4% vs. 15.7%, p = 0.005). Importantly, cardiovascular mortality (3.4% for ACN2 and 5.6% for MyV, p = 0.720) and valve‐related deaths were comparable. Conclusion: ACN2 showed superior long‐term hemodynamics and lower matched 4‐year mortality and stroke rates, though cardiovascular mortality and valve‐related deaths were comparable.
- 3 January 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (3) , 374-387
Impact of the COVID-19 Pandemic on Global TAVR Activity
- 3 January 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (3) , 374-387
Impact of the COVID-19 Pandemic on Global TAVR Activity
- 20 September 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (20) , 2581-2583
Neocommissural/Coronary Alignment With a Novel Balloon Expandable Transcatheter Aortic Valve
- 20 September 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (20) , 2581-2583
Neocommissural/Coronary Alignment With a Novel Balloon Expandable Transcatheter Aortic Valve
- 10 April 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (7) , 798-812
Abbreviated or Standard Antiplatelet Therapy in HBR Patients
- 10 April 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (7) , 798-812
Abbreviated or Standard Antiplatelet Therapy in HBR Patients
- Open Access
- 5 April 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 382, 68-75
Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication
- 5 April 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 382, 68-75
Open AccessAngiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication
- Open Access
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
Open AccessOne-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- Open Access
- 2 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (17) , 5210
Transcatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device
Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration.
- 2 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (17) , 5210
Open AccessTranscatheter Mitral Valve-in-Valve Implantation with the Balloon-Expandable Myval Device
Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration.